- Home
- TGB vs LIVN Comparison
TGB vs LIVN Comparison
Compare TGB & LIVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TGB | LIVN |
|---|---|---|
| Founded | 1966 | 1987 |
| Country | Canada | United Kingdom |
| Employees | N/A | N/A |
| Industry | Precious Metals | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.4B | 3.5B |
| IPO Year | 2002 | 2015 |
Fundamental Metrics
Financial Performance| Metric | TGB | LIVN |
|---|---|---|
| Price | $8.44 | $80.15 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 7 |
| Target Price | $9.50 | ★ $72.43 |
| AVG Volume (30 Days) | ★ 5.4M | 663.6K |
| Earning Date | 05-06-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 2.33 |
| Revenue | N/A | N/A |
| Revenue This Year | $71.94 | $9.79 |
| Revenue Next Year | $26.53 | $6.63 |
| P/E Ratio | ★ N/A | $34.25 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.28 | $48.82 |
| 52 Week High | $9.82 | $85.76 |
Technical Indicators
Market Signals| Indicator | TGB | LIVN |
|---|---|---|
| Relative Strength Index (RSI) | 50.30 | 49.93 |
| Support Level | $8.22 | $61.63 |
| Resistance Level | $9.08 | $81.83 |
| Average True Range (ATR) | 0.41 | 1.98 |
| MACD | -0.05 | 0.02 |
| Stochastic Oscillator | 18.44 | 46.31 |
Price Performance
Historical ComparisonAbout TGB Taseko Mines Ltd.
Trekor Metals Ltd is a North American copper producer with a development pipeline of minerals projects and properties in Canada and the United States. The company's properties include Gibraltar Mine, Florence Copper, Yellowhead Project, Aley Project, and New Prosperity.
About LIVN LivaNova PLC
UK-based LivaNova was born of a combination of Cyberonics in the US and Sorin in Italy. The medical-device firm is primarily focused on cardiopulmonary solutions (with heart-lung machines and oxygenation equipment) as well as neuromodulation devices for treatment-resistant epilepsy and depression. Following the merger, LivaNova divested its cardiac rhythm management, heart valve, and extracorporeal membrane oxygenation businesses. It derives roughly half of its revenue from the US market, another 21% from Europe, and the remainder from the rest of the world.